How to Get Crestor (Rosuvastatin) in New Hampshire

What Is Rosuvastatin and Why Is It Prescribed?

Rosuvastatin is a high-intensity statin approved by the FDA for treating hyperlipidemia and preventing atherosclerotic cardiovascular disease (ASCVD). AstraZeneca originally marketed it as Crestor, and multiple generic versions are now available [1]. The drug lowers LDL cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis.

The 2018 AHA/ACC Cholesterol Clinical Practice Guideline identifies rosuvastatin 20 to 40 mg as one of two high-intensity statin options (the other being atorvastatin 40 to 80 mg) expected to lower LDL-C by 50% or more [2]. In the JUPITER trial (N=17,802), rosuvastatin 20 mg daily reduced the primary endpoint of major cardiovascular events by 44% (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) compared to placebo in patients with LDL-C <130 mg/dL and hsCRP ≥ 2 mg/L [3]. That trial established rosuvastatin's role in primary prevention for patients who might not meet traditional LDL thresholds but carry inflammatory risk.

According to the FDA-approved prescribing information, rosuvastatin is indicated for adults and pediatric patients 8 years and older with heterozygous familial hypercholesterolemia, and for slowing the progression of atherosclerosis as part of a treatment strategy to lower total-C and LDL-C to target levels [1].

How to Get a Rosuvastatin Prescription in New Hampshire

Getting a prescription starts with a clinical evaluation. Any licensed prescriber in New Hampshire (MD, DO, NP, or PA) can write a rosuvastatin prescription after reviewing your cardiovascular risk factors, current medications, and baseline labs.

New Hampshire grants nurse practitioners full practice authority under RSA 326-B, meaning NPs can independently evaluate, diagnose, and prescribe statins without physician oversight [4]. Physician assistants prescribe under a collaborative agreement with a supervising physician, per the NH Board of Medicine. This means NH residents have broad access to qualified prescribers across primary care, cardiology, and internal medicine settings.

The prescribing process follows a standard sequence. Your provider will order a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) and hepatic transaminases (ALT and AST) before starting therapy [1]. A 10-year ASCVD risk calculation using the Pooled Cohort Equations helps determine whether statin therapy is appropriate and at what intensity. For patients aged 40 to 75 with LDL-C between 70 and 189 mg/dL and a 10-year ASCVD risk of 7.5% or higher, the AHA/ACC guidelines recommend initiating moderate- to high-intensity statin therapy [2].

Telehealth Options for Rosuvastatin in New Hampshire

Yes, telehealth is a fully legal and practical route to a rosuvastatin prescription in NH. New Hampshire enacted SB 387 in 2023, which codified permanent telehealth prescribing authority for licensed providers, removing the pandemic-era temporary provisions and making virtual statin prescriptions a routine clinical activity.

Several telehealth models serve NH residents. Direct-to-consumer platforms connect patients with board-certified physicians or NPs who can evaluate lipid panels, calculate ASCVD risk scores, and prescribe rosuvastatin during a single video visit. HealthRX offers telehealth statin consultations where a licensed provider reviews your labs and medical history, then sends a prescription to any NH pharmacy electronically.

A typical telehealth visit for statin initiation takes 15 to 25 minutes. You will need recent lab work (drawn within the past 12 months) or the provider will order new labs through a local Quest Diagnostics or Labcorp draw site. NH has Quest locations in Manchester, Nashua, Concord, and Salem, among others.

Dr. Paul Ridker, the lead investigator of the JUPITER trial, stated in the New England Journal of Medicine: "Rosuvastatin significantly reduced the incidence of major cardiovascular events among apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels" [3]. This finding expanded the clinical rationale for prescribing rosuvastatin to a broader population, including patients who might access care through telehealth rather than specialist referral.

New Hampshire Pharmacy Access and Pricing

Generic rosuvastatin is stocked at virtually every retail pharmacy in New Hampshire. CVS, Walgreens, Walmart, Rite Aid, and independent pharmacies across the state carry all standard dosage strengths: 5 mg, 10 mg, 20 mg, and 40 mg tablets.

Pricing varies by pharmacy and payment method. Without insurance, generic rosuvastatin costs between $10 and $45 for a 30-day supply depending on the dose and pharmacy. GoodRx and similar discount programs frequently bring the price to $10 to $15 for most strengths. Brand-name Crestor, when specifically prescribed, runs approximately $350 to $400 per month at retail price without insurance.

Mail-order pharmacies offer another option. Express Scripts, CVS Caremark, and Amazon Pharmacy all ship to New Hampshire addresses, often providing 90-day supplies at lower per-unit costs. For a 90-day supply of generic rosuvastatin 20 mg, mail-order pricing typically falls between $20 and $35.

New Hampshire's 503A-licensed compounding pharmacies can prepare custom rosuvastatin formulations for patients who cannot tolerate commercially available tablets. This is relevant for patients with specific allergies to inactive ingredients (such as lactose, which is present in some generic formulations) or for pediatric patients requiring liquid suspensions. Compounded rosuvastatin requires a patient-specific prescription and cannot be produced in bulk for general dispensing under 503A rules per FDA regulations [5].

Insurance Coverage and NH Medicaid Considerations

New Hampshire Medicaid does not cover brand-name Crestor for hyperlipidemia and ASCVD prevention. This is a direct formulary exclusion. Generic rosuvastatin may be available through the NH Medicaid preferred drug list, but coverage depends on the specific managed care organization administering the patient's benefits.

Commercial insurance plans in New Hampshire generally cover generic rosuvastatin on Tier 1 (preferred generic), with copays ranging from $0 to $15 per month. Brand-name Crestor, when covered, typically sits on Tier 3 (non-preferred brand) with copays of $40 to $75 per month or higher.

The 2019 AHA/ACC Focused Update on primary prevention noted: "Clinician-patient risk discussion should include a review of major risk factors, adherence to healthy lifestyle, the potential for ASCVD risk-reduction benefits, and the potential for adverse effects and drug-drug interactions" [6]. That guidance underscores the importance of discussing cost and access barriers during the prescribing conversation, since a patient who cannot afford their statin is unlikely to remain adherent.

For patients on Medicare Part D in New Hampshire, generic rosuvastatin is covered under most plans. The Centers for Medicare & Medicaid Services data show that rosuvastatin was among the top 10 most prescribed medications in Part D plans nationally in 2023, with an average 30-day cost to the beneficiary of $3.40 for generic formulations [7].

Prior Authorization Requirements in New Hampshire

Prior authorization for generic rosuvastatin is uncommon with commercial insurers in NH. Most plans approve it automatically at the pharmacy counter. Brand-name Crestor, however, almost always requires prior authorization since generic alternatives are available.

When prior authorization is required, the documentation typically includes a current fasting lipid panel showing LDL-C levels, documentation of the patient's ASCVD risk category, evidence of statin intolerance if requesting brand over generic (such as documented myalgia with two or more generic statins), and the prescriber's clinical rationale for the specific agent and dose. NH insurers generally process prior authorization requests within 24 to 72 hours. Urgent requests can be expedited to same-day review.

NH Medicaid prior authorization follows the state's Preferred Drug List criteria, managed through the Department of Health and Human Services. If generic rosuvastatin is not on the preferred list for a patient's specific managed care plan, the prescriber must submit clinical documentation demonstrating medical necessity or therapeutic failure with preferred alternatives such as atorvastatin or simvastatin.

A meta-analysis published in The Lancet (N=170,000 across 26 randomized trials) by the Cholesterol Treatment Trialists' Collaboration found that each 1 mmol/L (38.7 mg/dL) reduction in LDL-C with statin therapy reduced major vascular events by approximately 22% (RR 0.78; 95% CI 0.76 to 0.80) [8]. This evidence base supports prescribers in making the case for statin access when payers raise coverage barriers.

Transferring a Crestor Prescription to New Hampshire

Transferring an existing rosuvastatin prescription from another state to a New Hampshire pharmacy is straightforward. Federal law and NH Board of Pharmacy regulations permit one-time prescription transfers for non-controlled medications between retail pharmacies. Rosuvastatin is not a controlled substance, so it qualifies.

To transfer, call your current pharmacy and request they send the prescription to your preferred NH pharmacy. The receiving pharmacist will verify the prescription details, remaining refills, and prescriber information. Electronic transfers between pharmacies within the same chain (CVS to CVS, Walgreens to Walgreens) happen almost instantly. Transfers between different pharmacy chains typically complete within 2 to 4 hours.

If you are establishing care with a new provider in New Hampshire, they may prefer to write a new prescription rather than rely on a transfer. This gives them the opportunity to review your labs, assess your response to therapy, and confirm the dose is appropriate based on current guidelines.

Lab Monitoring Requirements in New Hampshire

Before starting rosuvastatin, providers in NH follow the same evidence-based monitoring protocol used nationwide. The baseline workup includes a fasting lipid panel (at least 9 to 12 hours fasting) and liver function tests (ALT and AST). Creatine kinase (CK) is not routinely ordered at baseline unless the patient reports pre-existing muscle symptoms [2].

Follow-up labs are typically drawn 4 to 12 weeks after initiation or dose adjustment to assess LDL-C response. The 2018 AHA/ACC guidelines recommend a fasting lipid panel at 4 to 12 weeks after starting or adjusting statin therapy, then every 3 to 12 months as clinically indicated [2]. If LDL-C does not decrease by at least 50% on rosuvastatin 20 to 40 mg (the expected high-intensity response), providers should assess adherence, dietary factors, and secondary causes of hyperlipidemia before adding non-statin therapies such as ezetimibe.

Liver function monitoring has been simplified. The FDA removed the recommendation for routine periodic liver enzyme testing from all statin labels in 2012, based on post-marketing data showing that serious liver injury with statins is rare and unpredictable, and routine monitoring did not reliably detect it [9]. A baseline ALT/AST is still recommended, but repeated liver panels are only necessary if symptoms of hepatotoxicity develop (unexplained fatigue, anorexia, right upper quadrant pain, dark urine, jaundice).

Renal function (eGFR) should be checked before starting rosuvastatin because the drug's pharmacokinetics are affected by kidney impairment. In patients with eGFR <30 mL/min/1.73 m², the starting dose should not exceed 5 mg daily, and the 40 mg dose is contraindicated [1].

Dosing and What to Expect After Starting Rosuvastatin

Rosuvastatin is taken once daily, with or without food, at any time of day. Unlike some older statins, it does not need to be taken in the evening because its half-life of approximately 19 hours provides sustained HMG-CoA reductase inhibition regardless of dosing time [1].

Standard starting doses are 10 to 20 mg daily for most adults. Patients requiring less aggressive LDL lowering may start at 5 mg. The maximum approved dose is 40 mg daily, reserved for patients who do not reach their LDL-C goal on 20 mg. In JUPITER, the 20 mg dose reduced LDL-C by a median of 50% from baseline [3].

Most patients notice no immediate effects from starting rosuvastatin. The drug works silently on hepatic cholesterol metabolism. LDL-C begins to drop within the first week, with the maximal effect typically seen by 4 weeks. Muscle-related side effects (myalgia) occur in approximately 5% to 10% of statin users across clinical practice, though rates in randomized trials are lower at around 1% to 2% above placebo, suggesting a significant nocebo component [10].

The METEOR trial (N=984) demonstrated that rosuvastatin 40 mg significantly reduced the progression of carotid intima-media thickness compared to placebo over 2 years (change in maximum CIMT: -0.0014 mm/year vs. +0.0131 mm/year; P<0.001), providing evidence of structural arterial benefit beyond lipid lowering [11].